Loading…

New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications

[Display omitted] In 2020, fifty-three new drugs, including forty small-molecules (thirty-six new chemical entities and four new diagnostic agents) and thirteen biologic drugs were approved by the U.S. Food and Drug Administration (FDA). This year, small-molecules continue to play a role in innovati...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2021-09, Vol.46, p.116340-116340, Article 116340
Main Authors: Cristina Mendonça Nogueira, Thais, Vinicius Nora de Souza, Marcus
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] In 2020, fifty-three new drugs, including forty small-molecules (thirty-six new chemical entities and four new diagnostic agents) and thirteen biologic drugs were approved by the U.S. Food and Drug Administration (FDA). This year, small-molecules continue to play a role in innovative treatments representing around 75% of all drugs accepted by FDA. The dominant therapeutic area was oncology, accounting for twenty-three new approvals, including thirteen new chemical entities, four new diagnostic agents, and thirteen biologic drugs. Recognizing the importance of small-molecules on cancer treatment, this review aims to provide an overview regarding the clinical applications and mechanism of action of the thirteen new small-molecules (excluding new diagnostic agents) approved by FDA in 2020.
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2021.116340